We also demonstrated that IAPP is downregulated in osteosarcoma cells and that treatment of these cells with Pramlintide, an FDA-approved analogue of IAPP used in the treatment of type 2 diabetes, altered the metabolic profiles of osteosarcoma cells with high or mid-range GC but had no effect on cells with low GC. Here, IAPP is linked to type 2 diabetes mellitus.